The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. ##STR00001##

The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. ##STR00001##

A lithium secondary battery including: a positive electrode which contains a positive electrode active material capable of absorbing and desorbing lithium; a negative electrode which contains a negative electrode active material capable of absorbing and desorbing lithium; and a non-aqueous electrolytic solution, wherein at least one of the positive electrode or the negative electrode contains a polymer that is a reaction product of a defined compound (A) and a defined compound (B) which is different from compound (A), and the non-aqueous electrolytic solution contains an additive (X). The additive (X) is at least one compound selected from the group consisting of: a carbonate compound having a carbon-carbon unsaturated bond, a carbonate compound having a halogen atom, an alkali metal salt, a sulfonic acid ester compound, a sulfuric acid ester compound, a nitrile compound, a dioxane compound, and a substituted aromatic hydrocarbon compound.

Disclosed is crystal form M of the proline hydroxylase inhibitor daprodustat, wherein the X-ray powder diffraction thereof, expressed in 2θ angles and using Cu-Ka radiation, has characteristic peaks at 4.7±0.2°, 6.5±0.2°, and 6.8±0.2°. Disclosed are the preparation method for and the use of crystal form M. The crystal form M has good light stability, high temperature stability and high humidity stability, good solubility, and high purity.

Disclosed is crystal form M of the proline hydroxylase inhibitor daprodustat, wherein the X-ray powder diffraction thereof, expressed in 2θ angles and using Cu-Ka radiation, has characteristic peaks at 4.7±0.2°, 6.5±0.2°, and 6.8±0.2°. Disclosed are the preparation method for and the use of crystal form M. The crystal form M has good light stability, high temperature stability and high humidity stability, good solubility, and high purity.

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

##STR00001##

The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

##STR00001##

Novel polycyclic compounds, synthesis methods and applications thereof are provided. The compound comprise a plurality of carbocyclic and/or heterocyclic structures having at least one group that emits visible light or fluorescence and at least one ultraviolet and/or visible (blue) light absorbing group covalently bonded to provide stability. The compounds can be used as a light conversion agent, dye, pigment, fluorescence agent, ultraviolet light or blue light absorber, and is applied to optical film, agricultural film, optical disk (disc), optical lens, goggles, skin care, makeup, lighting, coatings, adhesives, light stabilizers, or panels.

Novel polycyclic compounds, synthesis methods and applications thereof are provided. The compound comprise a plurality of carbocyclic and/or heterocyclic structures having at least one group that emits visible light or fluorescence and at least one ultraviolet and/or visible (blue) light absorbing group covalently bonded to provide stability. The compounds can be used as a light conversion agent, dye, pigment, fluorescence agent, ultraviolet light or blue light absorber, and is applied to optical film, agricultural film, optical disk (disc), optical lens, goggles, skin care, makeup, lighting, coatings, adhesives, light stabilizers, or panels.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

##STR00001##

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.